Skip to main content
News Icon

Publication

Corona study published in Nature Communications

After the preliminary publication on the preprint server medRxiv in May 2020, the study by scientists of the University of Bonn about the first coronavirus outbreak in Germany in the community of Gangelt has been published in the renowned scientific journal Nature Communications.

The study was already pre-published in May 2020 to meet the demand of scientific journals to make findings about COVID-19 available to science and the public as early as possible.


Publication

Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event; Hendrik Streeck, Bianca Schulte, Beate M. Kümmerer, Enrico Richter, Tobias Höller, Christine Fuhrmann, Eva Bartok, Ramona Dolscheid, Moritz Berger, Lukas Wessendorf, Monika Eschbach-Bludau, Angelika Kellings, Astrid Schwaiger, Martin Coenen, Per Hoffmann, Birgit Stoffel-Wagner, Markus M. Nöthen, Anna-Maria Eis-Hübinger, Martin Exner, Ricarda Maria Schmithausen, Matthias Schmid and Gunther Hartmann; Nature Communications, DOI: http://dx.doi.org/10.1038/s41467-020-19509-y

The Cluster of Excellence ImmunoSensation2 provided no funding for the study.

Related news

Kathrin Leppek Publication PM

Publication

Starting points for the control of protein synthesis

—Bonn researchers develop a versatile toolbox for the characterization of IRESes in cells.
View entry
Pandyra Publication Graphical Abstract

Publication

Genetic mutation affects survival after viral infection

—Scientists discovered that haploinsufficiency in the Pax5 gene affects antiviral responses. The study was led by Prof. Dr. Aleksandra Pandyra from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn in collaboration with Prof. Dr. Arndt Borkhardt, Clinic Director at the Pediatric Oncology at the University Hospital Düsseldorf. The findings were published in the latest edition of EMBO Molecular Medicine.
View entry
AG Kürthen Multiple Sclerosis Bonn

Publication

Potential target for MS therapy discovered

—Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system caused by the immune system. B cells, which are a type of white blood cell, play a role in the development of MS and are thus a target for therapies. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the FAU Erlangen-Nuremberg identified the membrane protein MLC1 as a potential target antigen in MS. The results of the work have now been published in the renowned journal “Neurology Neuroimmunology & Neuroinflammation”.
View entry

Back to the news overview